depression - Page 1 | CARLAT PUBLISHING

Lithium Goes Mainstream

April 20, 2026

Chris Aiken, MD and Kellie Newsome, PMHNP

In the 1950s, a young Danish psychiatrist named Mogens Schou staked his career — and his family — on a mineral most of his colleagues dismissed as dangerous nonsense. This is the story of how lithium went from fringe curiosity to the gold standard for bipolar disorder, and the bitter scientific battle that nearly derailed it.

Lithium: From 7UP to Table Salt

April 13, 2026

Chris Aiken, MD and Kellie Newsome, PMHNP

Before lithium became a cornerstone of psychiatry, it was in soda, spa water, and salt shakers. Trace lithium’s journey from Victorian health fad to life-saving mood stabilizer, and discover why the uric acid theory that launched it may be making a comeback.

Depression Rarely Travels Alone

March 7, 2026

Daniel Carlat, MD

We tend to blame the meds.

But what if the real reason a patient isn’t improving… is because we’re treating the wrong thing?

Rapid-acting Medications

February 28, 2026

Daniel Carlat, MD

There are times in treatment when the usual pace just won’t do. That’s when we reach for rapid-acting medications.

Difficult-to-Treat Depression

February 19, 2026

Daniel Carlat, MD

Depression distorts memory. Measurement restores it.

Flow Device: FDA Approval vs Real-World Effectivenes

February 9, 2026

Daniel Carlat, MD

In December 2025, Flow did in fact receive FDA Approval, based on data from the Empower trial. Before that, it had been marketed under FDA clearance—a lower evidentiary bar. That correction matters—and it sharpens the question many subscribers have been asking me: How much does FDA approval tell us about real‑world effectiveness?

Research Update

Vitamin D Has Dose-Dependent Effect on Depressive Symptoms

January 28, 2026

Alex Evans, PharmD, MBA.

Alex Evans, PharmD, MBA. Dr. Evans has no financial relationships with companies related to this material.

Investigators reveal measurable antidepressant effects of Vitamin D but limited benefits for anxiety, quality of life, or depression remission.

Research Update

Pentoxifylline as an Add-On Therapy for Major Depressive Disorder

January 9, 2026

Sy Clark, MD

Sy Clark, MD. Dr. Clark has no financial relationships with companies related to this material.

A decades-old vascular drug unexpectedly lifts mood—offering a fresh angle on treatment-resistant depression.

Research Update

Ketamine Shows Only Modest Advantage Over Midazolam in Inpatient Depression Treatment

January 1, 2026

Victoria Hendrick, MD

Victoria Hendrick, MD. Dr. Hendrick has no financial relationships with companies related to this material.

Is ketamine really more effective than an active placebo for inpatient depression? A new randomized trial puts ketamine head-to-head with midazolam, and the results may temper early enthusiasm.

Clinical Update

Managing the Side Effects of Lithium

January 1, 2026

Jesse Koskey, MD.

Jesse Koskey, MD. Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, UC Davis Health, Sacramento, CA.

Dr. Koskey has no financial relationships with companies related to this material.

Lithium’s reputation for harsh side effects keeps many patients away—but most are manageable with smart, evidence-based care.

Items Tagged with 'depression'

ARTICLES

Lithium Goes Mainstream

Lithium: From 7UP to Table Salt

Depression Rarely Travels Alone

Rapid-acting Medications

Difficult-to-Treat Depression

Flow Device: FDA Approval vs Real-World Effectivenes

Vitamin D Has Dose-Dependent Effect on Depressive Symptoms

Pentoxifylline as an Add-On Therapy for Major Depressive Disorder

Ketamine Shows Only Modest Advantage Over Midazolam in Inpatient Depression Treatment

Managing the Side Effects of Lithium

Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Treating BPD Series, Episode 2: Transference-Focused Psychotherapy—From Splitting to Coherence with Frank Yeomans, MD, PhD

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us